Table 2.
Demographic and clinical characteristics of primary nonresponders at the time of starting infliximab therapy
| Case no. | Age (years)/sex | RA duration (months) | DAS28-ESR | HAQ | CRP (mg/dl) | ESR (mm/h) | Anti-CCP Abs (U/ml) | IgM RF (IU/ml) | SJC28 (SJC66) | TJC28 (TJC68) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 70/F | 36 | 6.7 | 1.75 | 2.9 | 52 | 591 | 255 | 5 (6) | 16 (17) |
| 2 | 36/F | 5 | 6.9 | 2.25 | 1.1 | 42 | Negative | Negative | 13 (28) | 16 (31) |
| 3 | 61/M | 3 | 7.1 | 2.75 | 13.3 | 96 | 145 | 404 | 9 (10) | 13 (23) |
| 4 | 69/M | 14 | 5.7 | 2.00 | 10.8 | 77 | 98 | Negative | 5 (7) | 3 (5) |
| 5 | 65/M | 4 | 5.7 | 1.00 | 2.0 | 43 | 75 | 120 | 5 (5) | 5 (5) |
| 6 | 79/M | 7 | 6.1 | 3.00 | 6.0 | 93 | 1710 | 258 | 5 (13) | 4 (12) |
| 7 | 71/F | 108 | 6.8 | 1.87 | 2.1 | 96 | 24 | Positive | 8 (15) | 8 (15) |
| 8 | 70/F | 120 | 5.1 | 1.65 | 2.0 | 26 | 22 | 21 | 5 (13) | 5 (13) |
| 9 | 63/F | 112 | 5.3 | 0.87 | 0.6 | 40 | 655 | Positive | 1 (1) | 5 (5) |
Data were obtained immediately before starting infliximab therapy
RA rheumatoid arthritis, DAS28 disease activity score for 28 joints, HAQ health assessment questionnaire score, CRP C-reactive protein, ESR erythrocyte sedimentation rate, anti-CCPAbs anti-cyclic citrullinated peptide antibodies, RF rheumatoid factor, SJC28 swollen joint count in 28 joints, TJC28 tender joint count in 28 joints